بيان صحفي تجاري

Never too late to learn the basics

14 Feb 2020

At an educational seminar in the beginning of February 2020 on producing oral solid dosage forms, GEA’s Dr Harald Stahl teamed up with experts from industry and academia to elucidate the fundamental relationship between granulation and tableting, discuss possible manufacturing issues and apply best practices.

Batch granulation plant

A batch granulation plant from GEA. (Photo: GEA)

During the recent “Granulation and Tableting Seminar” in Mannheim, Germany (4–6 February, 2020), organized by Concept Heidelberg, GEA’s Dr Harald Stahl, Head of Innovation and Strategy Pharma & Healthcare, took to the podium with Dr Michael Braun, Head of Late Stage Development at Boehringer Ingelheim, and Dr Karl G. Wagner, Professor for Pharmaceutical Technology and Biopharmacy at the University of Bonn, to discuss the fundamentals of granulation and tableting. With a particular focus on how to avoid capping, sticking and weight and content fluctuations, the comprehensive program covered “everything from raw material characterization, fluid bed granulation, high-shear processing and roller compaction to handling highly potent compounds and a comparison of the various available technologies,” noted Dr Stahl.

Hosting 35 participants from German-speaking countries (DACH), the audience comprised representatives from Big Pharma companies, smaller organizations and engineering businesses. “We had an interesting mix of R&D professionals, production staff and personnel from other functions, such as quality control and engineering,” added Harald. Dr Stahl, who gave presentations on the fundamentals of granulation, scale-up issues, high shear granulation and continuous manufacturing, moderated a troubleshooting session and chaired the overall event, commented: “The speaker profile was perfectly balanced, with talks from a supplier company, a pharmaceutical organization and academia. The three different points of view were very well received.”

With the aid of a live webcam, for instance, Prof. Wagner demonstrated the compression behavior of materials affected by (a) plastic deformation (with plasticine), (b) brittle fraction (with cornflakes) and (c) elastic deformation. He also showed how the addition of a lubricant can help to avoid material sticking to punches and dies while, at the same time, reducing the binding materials affected by plastic deformation. Dr Braun also gave an industry perspective of the “fundamentals” part of the program, which was deemed to be an excellent complement to Dr Stahl’s presentation and a valuable addition to the agenda.

During the informative and popular troubleshooting session, and reminiscent of a recent GEA article that likened pharmaceutical manufacturing to a game of chess, the take home message was that although most tableting problems only occur at the production stage, the root cause is generally either an upstream process issue (such as granulation) or a formulation error.

Dr. Harald Stahl

Dr. Harald Stahl, Head of Innovation and Strategy, Pharma & Healthcare GEA. (Photo: GEA)

“It’s often the case that the R&D team develops an oral dosage form that works perfectly well on a slow-running benchtop press … but doesn’t deliver the same results when scaled up to an industrial machine,” observed Harald.

“The event showcased the magic triangle of an all-inclusive approach to raw materials, the fundamentals of granulation and tableting, and the influence of those raw materials on compression behavior. It also highlighted that the root cause of tableting issues is most often not the press and reinforced the notion that critical decisions need to made early on during development. This is when collaboration is key to ensuring that when a formulation reaches commercial-stage production, industrial-scale machines are actually capable of reaching the output values that they’ve been designed to achieve, problem free!”

“Judging by the excellent feedback we've received, this was a very worthwhile event that, once again, confirms the ongoing value of addressing the basics of pharma manufacturing — whatever your level of experience and time in the industry,” concluded Harald.

Future events are planned for 29 September –1 October 2020 in Prague (in English) and 23–25 February 2021 in Mannheim (in German).

Media Relations

GEA Group Aktiengesellschaft

Peter-Müller-Str. 12


40468

Düsseldorf


Germany

+49 211 9136-0

About GEA

نبذة عن GEA تعتبر GEA واحدة من أكبر الموردين لصناعة معالجة الأغذية ومجموعة واسعة من الصناعات الأخرى والتي حققت إيرادات موحدة بلغت قُرابة 4.9 مليار يورو في عام 2019. تتخصص المجموعة الدولية للتكنولوجيا في الآلات والمصانع، وكذلك تكنولوجيا

نبذة عن GEA تعتبر GEA واحدة من أكبر الموردين لصناعة معالجة الأغذية ومجموعة واسعة من الصناعات الأخرى والتي حققت إيرادات موحدة بلغت قُرابة 4.8 مليار يورو في عام 2018. تتخصص المجموعة الدولية للتكنولوجيا في الآلات والمصانع، وكذلك تكنولوجيا المعالجة والمكونات. توفر GEA حلولًا مستدامة للطاقة لعمليات الإنتاج المتطورة في أسواق المستخدمين النهائيين المتنوعة، وتوفر مجموعة خدمات شاملة. تحقق المجموعة قُرابة 70 بالمائة من إيراداتها في قطاع الأغذية والمشروبات الذي يتمتع بنمو مستدام طويل الأجل. واعتبارًا من 31 ديسمبر 2018، وظفت الشركة قرابة 18,500 شخصًا حول العالم. إن GEA هي شركة رائدة في السوق والتكنولوجيا في مجالات أعمالها. الشركة مدرجة في مؤشر MDAX الألماني (G1A، WKN 660 200)، ومؤشر STOXX® Europe 600 ومؤشرات MSCI العالمية للاستدامة. مزيد من المعلومات متاح على شبكة الإنترنت على gea.com. إذا كنت لا ترغب في تلقي أي معلومات أخرى من GEA، فيرجى إرسال بريد إلكتروني إلى pr@gea.com.
تلقَّ الأخبار من GEA

ابق على اتصال مع ابتكارات وقصص GEA من خلال الاشتراك في النشرات المقدمة من GEA.

تواصل معنا

نحن هنا لنقدم لك أي مساعدة تطلبها، فتلك هي مهمتنا! مع تفاصيل قليلة فقط سوف نكون قادرين على الرد على استفساراتك.